---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-059753"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T16:04:23.951681+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Fulcrum Therapeutics Q3 2023: net loss $24M, Phase 3 enrollment complete, cash runway extended into 2026

## Summary
- Completed enrollment in Phase 3 REACH trial of losmapimod for FSHD; topline data expected Q4 2024.
- FDA lifted clinical hold for pociredir in sickle cell disease; Phase 1b trial reinitiation underway with amended protocol.
- Net loss of $24.0M for Q3 2023 vs $23.7M in prior-year quarter; R&D expenses increased to $18.2M.
- Cash, cash equivalents, and marketable securities $257.1M as of Sep 30, 2023; cash runway extended into 2026.
- Collaboration revenue $0.8M, down from $1.2M in Q3 2022.

## SEC filing metadata
- accession: 0000950170-23-059753
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000095017023059753/0000950170-23-059753-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000095017023059753/fulc-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-059753
- JSON: https://secwatch.observer/filing/0000950170-23-059753.json
- Plain text: https://secwatch.observer/filing/0000950170-23-059753.txt

## Key facts
- Earnings Releases
  Fulcrum Therapeutics, Inc. reported third quarter of 2023 results: revenue $0.8 million, net income $24.0 million.
  - Period: third quarter of 2023
  - Revenue: $0.8 million
  - Net income: $24.0 million
  - Result: reported results
  source text: cash, cash equivalents, and marketable securities were $257.1 million, as compared to $202.9 million as of December 31, 2022. • Collaboration Revenue: Collaboration revenue was $0.8 million for the third quarter of 2023 as compared to $1.2 million for the third quarter of 2022. • R&D Expenses: Research and development expenses were $18.2 million for the third
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680581/000095017023059753/0000950170-23-059753-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.